{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-051575","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.894411+00:00","generated_at":"2026-05-14T23:57:46.034307+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Onconetix shareholders approve reverse stock split up to 1-for-10","bullets":["Reverse split proposal approved with 1,301,918 for, 253,378 against, 1,393 abstentions.","Board may implement one or more splits at ratios between 1:2 and 1:10 within one year, not exceeding 1:100 aggregate.","Adjournment proposal also approved with 1,332,088 for, 223,071 against, 1,530 abstentions.","Reverse split authorized without further stockholder approval; exact ratio to be set by the board."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051575","json":"https://secwatch.observer/filing/0001213900-26-051575.json","markdown":"https://secwatch.observer/filing/0001213900-26-051575.md","text":"https://secwatch.observer/filing/0001213900-26-051575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/0001213900-26-051575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/ea0288982-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:46.034307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67528a6432e915e4366ea9f60ad33179bb338f1f","claim":"Onconetix, Inc. shareholders approved Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to th at the 2026-04-30 meeting.","evidence_excerpt":"1. Reverse Stock Split Proposal The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,301,918 253,378 1,393","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/0001213900-26-051575-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-04-30"}],"fact_type":"shareholder_vote"},{"claim_id":"861025390c1f1b99cad5412ad377ad7ebda5023d","claim":"Onconetix, Inc. shareholders approved Approval of the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. at the 2026-04-30 meeting.","evidence_excerpt":"2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,332,088 223,071 1,530","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026051575/0001213900-26-051575-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-04-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}